Seeing further.


We’re advancing our RNA-based treatments so patients with cancers and rare diseases can enjoy the moments that matter.

Learn More

Transforming Immunity. Restoring Hope.

We’re committed to redefining the treatment of certain cancers and rare diseases.

Learn More

Scientists. Believers. People.

At Idera, we’re working hard to translate our nucleic acid science into life-changing medicines.

Discover Idera

The Latest

Keep up with what’s happening at Idera Pharmaceuticals.


Idera Pharmaceuticals Presents Positive Phase 1 Data for Intratumoral IMO-2125 in Combination with Ipilimumab Demonstrating an Overall Response Rate (ORR) of 44% in Melanoma Patients Refractory to Anti-PD1 Therapy

- Data from Ongoing Phase 1/2 Study Presented at the 2017 European Society for Medical Oncology… Read more 

Idera Pharmaceuticals Presents Pre-Clinical Data from IMO-2125 Treatment in Combination with Ipilimumab that Demonstrates Induction of Durable Anti-tumor Responses Associated with Tumor-Specific Memory

Clinical Data from Ongoing Phase 1/2 Trial of IMO-2125 in anti-PD-1 Refractory Melanoma to be… Read more 

Idera to Host Investor Conference Call on Monday, September 11, 2017 at 9:00 A.M. E.T.

CAMBRIDGE, Mass. and EXTON, Pa. , Sept. 06, 2017 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc.… Read more 

Learn More


Idera Pharmaceuticals, Inc. Events

Idera Pharmaceuticals, Inc. Events… Read more 

Learn More